Search Within

GDMT, Medicine

Formats
  1. Journal Article (920)
  2. Meeting Abstract (825)
  3. Review (46)
  4. Book Section (38)
  5. Editorial (29)
  6. Guidelines (18)
  7. Correspondence (7)
  8. Research Letter (1)
Groups
  1. Gynecology Disease Management Team (1884)
  2. Department of Medicine (1875)
  3. Solid Tumor Oncology Division (1873)
  4. Gynecologic Medicine Service (1833)
  5. Surgery (577)
  6. GDMT, Surgery (462)

More Groups

People
  1. Carol Aghajanian (609)
  2. Martee Hensley (290)
  3. Nadeem Abu-Rustum (277)
  4. Roisin O'Cearbhaill (272)
  5. Vicky Makker (265)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (47)
  2. 2024 (159)
  3. 2023 (165)
  4. 2022 (196)
  5. 2021 (146)
  6. 2020 (173)

More Years

Publications
  1. Gynecologic Oncology (416)
  2. Journal of Clinical Oncology (414)
  3. International Journal of Gynecological Cancer (148)
  4. Annals of Oncology (106)
  5. Clinical Cancer Research (62)
  6. Cancer (37)

More Publications

Publishers
  1. Elsevier Inc. (495)
  2. American Society of Clinical Oncology (445)
  3. Lippincott Williams & Wilkins (173)
  4. American Association for Cancer Research (137)
  5. Oxford University Press (128)
  6. Nature Publishing Group (71)

More Publishers

Results (1884)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study
    Journal Article

    Ehmann, S.; Shay, K.; Zhou, Q.; Iasonos, A.; Sonoda, Y.; Gardner, G. J.; Long Roche, K.; Zammarrelli, W. A. 3rd; Yeoushoua, E.; O'Cearbhaill, R. E.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • State of the biomarker dcience in ovarian cancer: A National Cancer Institute Clinical Trials Planning Meeting Report
    Journal Article

    Ethier, J. L.; Fuh, K. C.; Arend, R.; Konecny, G. E.; Konstantinopoulos, P. A.; Odunsi, K.; Swisher, E. M.; Kohn, E. C.; Zamarin, D.
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Germline SMARCA4 deletion as a driver of uterine cancer: An atypical presentation
    Journal Article

    Navitski, A.; Al-Rawi, D. H.; Makker, V.; Weigelt, B.; Zamarin, D.; Liu, Y.; Arnold, A. G.; Chui, M. H.; Mandelker, D. L.; Walsh, M.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Risk stratification of stage I grade 3 endometrioid endometrial carcinoma in the era of molecular classification
    Journal Article

    Zammarrelli, W. A. 3rd; Kim, S. H.; Da Cruz Paula, A.; Rios-Doria, E. V.; Ehmann, S.; Yeoshoua, E.; Hanlon, E. J.; Zhou, Q.; Iasonos, A.; Alektiar, K. M.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • MEDI1191 (IL-12 MRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (c/sc) lesions
    Meeting Abstract

    Abadier, M.; Jennings, E.; Eyles, J.; Martin, P.; Pilataxi, F.; Wu, Y.; Chen, X.; Azaro, A.; Ridgway, B.; Phillips, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: Part 1 results
    Meeting Abstract

    Friedman, C.; Carvajal, R.; Davar, D.; Castanon, E.; Ascierto, P.; Calvo, E.; O'Hara, M.; Powell, S.; Shapira-Frommer, R.; Garralda, E.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors
    Meeting Abstract

    Shapiro, G. I.; Basu, B.; El-Khoueiry, A.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)
    Meeting Abstract

    Spigel, D.; Spira, A.; Zamarin, D.; McDermott, D. F.; Luke, J.; Heymach, J. V.; Previs, R.; Sullivan, R.; Gandhi, L.; Azrilevich, A.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors
    Meeting Abstract

    Carneiro, B. A.; Zamarin, D.; Marron, T.; Mehmi, I.; Patel, S. P.; Subbiah, V.; El-Khoueiry, A.; Grand, D.; Garcia-Reyes, K.; Goel, S.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors
    Meeting Abstract

    Purroy, N.; Durham, N.; Phillips, M.; Hattersley, M. M.; Jung, L.; Davar, D.; Zamarin, D.; Johanns, T. M.; Puzanov, I.
    Cancer Research (2022)

    Fulltext@MSK | Save